S85 通过 IMPACT-III 评估哥伦比亚儿科炎症性肠病患者的健康生活质量

V. Parra-izquierdo, J. Frías-Ordoñez, Consuelo Romero-Sanchez, F. Puentes-Manosalva, Diana Mora, John Garces, C. Cuadros, Fernando Sarmiento, Melquisedec Vargas, Carolina Samper, Mariastella Serrano
{"title":"S85 通过 IMPACT-III 评估哥伦比亚儿科炎症性肠病患者的健康生活质量","authors":"V. Parra-izquierdo, J. Frías-Ordoñez, Consuelo Romero-Sanchez, F. Puentes-Manosalva, Diana Mora, John Garces, C. Cuadros, Fernando Sarmiento, Melquisedec Vargas, Carolina Samper, Mariastella Serrano","doi":"10.14309/01.ajg.0000996084.75247.15","DOIUrl":null,"url":null,"abstract":"Background: Among patients with ulcerative colitis (UC), prior exposure to biologics or advanced therapies is associated with reduced response to future therapies, which may lead to treatment discontinuation. Therapy persistence is a proxy of real-world treatment performance and is important to achieve optimal clinical outcomes. This study compared persistence among advanced therapy-experienced patients with UC initiated on ustekinumab, an anti-interleukin 12/23 antibody, or adalimumab","PeriodicalId":188050,"journal":{"name":"The American Journal of Gastroenterology","volume":"89 1","pages":"S23 - S23"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"S85 Evaluation of Quality of Life in Health by IMPACT-III in Colombian Pediatric Patients With Inflammatory Bowel Disease\",\"authors\":\"V. Parra-izquierdo, J. Frías-Ordoñez, Consuelo Romero-Sanchez, F. Puentes-Manosalva, Diana Mora, John Garces, C. Cuadros, Fernando Sarmiento, Melquisedec Vargas, Carolina Samper, Mariastella Serrano\",\"doi\":\"10.14309/01.ajg.0000996084.75247.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Among patients with ulcerative colitis (UC), prior exposure to biologics or advanced therapies is associated with reduced response to future therapies, which may lead to treatment discontinuation. Therapy persistence is a proxy of real-world treatment performance and is important to achieve optimal clinical outcomes. This study compared persistence among advanced therapy-experienced patients with UC initiated on ustekinumab, an anti-interleukin 12/23 antibody, or adalimumab\",\"PeriodicalId\":188050,\"journal\":{\"name\":\"The American Journal of Gastroenterology\",\"volume\":\"89 1\",\"pages\":\"S23 - S23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The American Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14309/01.ajg.0000996084.75247.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/01.ajg.0000996084.75247.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:在溃疡性结肠炎(UC)患者中,之前接触过生物制剂或先进疗法与对未来疗法的反应降低有关,这可能会导致治疗中断。治疗持续性是真实世界治疗效果的代表,对于实现最佳临床疗效非常重要。本研究比较了有晚期治疗经验的 UC 患者在开始使用抗白细胞介素 12/23 抗体乌斯特库单抗或阿达木单抗后的持续治疗情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
S85 Evaluation of Quality of Life in Health by IMPACT-III in Colombian Pediatric Patients With Inflammatory Bowel Disease
Background: Among patients with ulcerative colitis (UC), prior exposure to biologics or advanced therapies is associated with reduced response to future therapies, which may lead to treatment discontinuation. Therapy persistence is a proxy of real-world treatment performance and is important to achieve optimal clinical outcomes. This study compared persistence among advanced therapy-experienced patients with UC initiated on ustekinumab, an anti-interleukin 12/23 antibody, or adalimumab
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信